Company news

Neurogene Inc. news in 2026

Neurogene Inc.'s news releases, calls and decks from 2026, newest first.

View company

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 5, 2026

Neurogene to Participate in Upcoming Investor Conferences

November 3, 2026

Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome

October 27, 2026

Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress

October 20, 2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

August 11, 2026

Neurogene Inc. Announces Pricing of $125 Million Public Offering

July 1, 2026

Neurogene Inc. Announces Proposed Public Offering

June 30, 2026

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

June 29, 2026

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

June 8, 2026

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

May 12, 2026

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

May 12, 2026

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy

April 28, 2026

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

April 20, 2026

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

March 23, 2026

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

March 10, 2026

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

February 25, 2026

Neurogene to Participate in Upcoming Investor Conferences

February 5, 2026

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 4, 2026

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

January 12, 2026

Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Decks in 2026